Gout Explained: Symptoms, Uric Acid, Flares, and Long-Term Prevention

Gout is common, painful, and often undertreated

Gout matters because it is both intensely symptomatic and highly preventable. A first flare may look like an isolated orthopedic problem: a red, swollen big toe at two a.m., maybe after dehydration, alcohol, or a large meal. Yet the biology is systemic: monosodium urate crystals form when serum urate remains above its saturation point, then the innate immune system reacts abruptly. For patients, that means recurrent attacks and fear of movement. For clinicians, it means a treatable inflammatory arthritis that is still commonly managed only with episodic steroids or pain medicine, leaving crystal burden untouched.

What uric acid does, and when it becomes gout

Uric acid is the end product of purine metabolism. Most people with hyperuricemia never develop gout, which is why urate alone does not diagnose the disease. Gout begins when urate concentration, tissue temperature, pH, and local factors favor crystal deposition in joints or soft tissues. The classic threshold is about 6.8 mg/dL, although risk rises progressively, especially with chronic kidney disease, diuretic exposure, obesity, insulin resistance, and genetic variation in renal urate transport.

Why flares start fast

When macrophages encounter crystals, they activate the NLRP3 inflammasome and release interleukin-1 beta, a cytokine that drives neutrophil influx and severe pain. That explains why flares can peak quickly and why colchicine, nonsteroidal anti-inflammatory drugs, glucocorticoids, and interleukin-1 blockade can work when used appropriately. It explains why lowering urate is preventive therapy, not immediate analgesia.

Symptoms: more than a sore toe

Podagra, inflammation of the first metatarsophalangeal joint, is the textbook presentation, but gout is broader. Flares often cause explosive pain, warmth, swelling, shiny erythema, and marked tenderness to light touch. Ankles, knees, wrists, fingers, elbows, and bursae may be involved. Between attacks, examination may be normal, which can mislead both patient and clinician. With years of undertreated hyperuricemia, tophi can develop: firm urate deposits in soft tissue that may erode bone and impair function.

A practical example: a 58-year-old man with hypertension and stage 3 chronic kidney disease develops three episodes of acute ankle swelling in a year. Each improves with prednisone. His urate is 8.9 mg/dL between attacks. The pattern is not “just aging joints.” Recurrent, abrupt, self-limited inflammatory episodes plus persistent hyperuricemia make gout likely, though aspiration for crystal confirmation remains the diagnostic reference standard when feasible, especially if infection is plausible.

Diagnosis and the common misconception about urate levels

The most important misconception is that a normal serum urate during pain rules out gout. It does not. Urate can fall during acute inflammation, so measurement is often more useful after the flare resolves. Conversely, asymptomatic hyperuricemia is not gout and usually is not treated solely because the number is high. The clinical question is whether crystals have caused inflammatory disease or tissue deposition.

Joint aspiration showing negatively birefringent needle-shaped crystals under polarized microscopy remains definitive and can simultaneously evaluate for infection. Ultrasound may show the double-contour sign, and dual-energy CT can identify urate deposition, but imaging should complement, not replace, clinical judgment. The 2015 ACR/EULAR classification criteria improved research standardization; bedside diagnosis still depends on timing, distribution, comorbidities, medication exposures, and whether septic arthritis has been reasonably excluded.

Treating flares while thinking beyond the flare

The 2020 American College of Rheumatology guideline strongly supports colchicine, nonsteroidal anti-inflammatory drugs, or glucocorticoids as first-line flare therapy, selected according to kidney function, cardiovascular risk, anticoagulation, diabetes, infection concern, and prior response. Low-dose colchicine is favored over older high-dose regimens because trials show comparable benefit with less gastrointestinal toxicity.

The deeper decision is whether to start urate-lowering therapy. ACR strongly recommends it for patients with tophi, radiographic damage attributable to gout, or frequent flares, generally defined as two or more yearly. It is conditionally considered after a first flare when risk is high, such as very elevated urate, chronic kidney disease, or urolithiasis. This is where rheumatology reasoning matters: repeated anti-inflammatory rescue treats the smoke; sustained urate lowering removes the fuel.

Long-term prevention: treat to target, not to symptoms alone

Allopurinol remains preferred first-line urate-lowering therapy for most patients, including many with chronic kidney disease, when started low and titrated carefully. Febuxostat is an alternative, but cardiovascular context matters because the CARES trial raised mortality concerns while FAST offered more reassuring data in a different population. Probenecid can help selected underexcretors but is limited by kidney function and stone risk. Pegloticase is reserved for severe, refractory tophaceous disease and requires careful immunogenicity management.

Treat-to-target is the central concept. The ACR recommends titrating therapy to serum urate below 6 mg/dL; lower targets are often used in heavy tophaceous disease to accelerate crystal dissolution. Because mobilizing crystals can trigger early flares, anti-inflammatory prophylaxis with colchicine, an NSAID, or low-dose glucocorticoid is commonly continued for at least three to six months, individualized to risk. Stopping urate-lowering therapy after symptoms improve is a common cause of relapse.

Lifestyle helps, but gout is not simply a diet failure

Diet and alcohol counseling are useful, but moralizing gout is inaccurate and clinically counterproductive. Beer, spirits, high-fructose beverages, and large purine loads can contribute; weight reduction and limiting sweetened drinks may lower urate modestly. Yet genetics, kidney excretion, medications, and comorbid metabolism often dominate. Patients should not be left believing that perfect eating is required before evidence-based pharmacologic prevention is considered.

Synthesis

Current evidence supports a clear strategy: confirm the inflammatory pattern, control flares safely, identify patients who benefit from urate lowering, and titrate to a measurable target. Uncertainty remains around optimal imaging use, individualized flare prophylaxis, and cardiovascular risk interpretation for specific drugs. The open question is not whether gout is preventable, but how reliably health systems deliver sustained, target-based care.